A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Required: EGFR exon 19 deletion

Required: EGFR l858r

Required: EGFR t790m

Must have received: neoadjuvant or adjuvant therapy — nonmetastatic

Participants who have received prior neoadjuvant, adjuvant therapies with curative intent for nonmetastatic disease must have completed treatment for at least 12 months prior to the development of recurrent or metastatic disease

Must have received: first- or second-generation EGFR-TKI — locally advanced or metastatic

Participant who only received one line of first- or second-generation EGFR-TKI in the locally advanced or metastatic setting and have documented radiological progression prior to enrolling in the study

Cannot have received: third-generation EGFR-TKI (osimertinib)

Treatment with prior third-generation EGFR-TKI (e.g., osimertinib)

Cannot have received: first- or second-generation EGFR-TKI (erlotinib, gefitinib)

Exception: within 8 days of the first dose of study intervention or 5 half-lives, whichever is the longer

Treatment with a first- or second-generation EGFR-TKI (e.g., erlotinib or gefitinib) within 8 days of the first dose of study intervention or 5 half-lives, whichever is the longer

Cannot have received: cytotoxic chemotherapy

Exception: within 14 days of the first dose of study intervention or 5 half-lives, whichever is longer

Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study taken within 14 days of the first dose of study intervention or 5 half lives, whichever is longer

Cannot have received: investigational agent

Exception: within 28 days or 5 half-lives, whichever is longer, before Screening Visit

Participants participated in any interventional clinical study or had been treated with any investigational drugs within 28 days or 5 half-lives, whichever is longer, before Screening Visit